Recruiting
Phase 2

Excimer Light

Sponsor:

University of British Columbia

Code:

NCT01802177

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Interventions

UVB excimer light

Study Details

Brief summary:

Alopecia Areata (AA) is a chronic autoimmune inflammatory disease causing nonscarring hair loss. Many treatment modalities have been found to be helpful in AA, however, none on them cure the disease. UVB excimer light has recently emerged as a new therapeutic modality in many dermatologic diseases. There are no prospective randomized controlled trials evaluating the efficacy and safety of UVB excimer light in AA. We plan on conducting a prospective split lesion single-blinded randomized clinical trial to assess efficacy and safety of UVB excimer light in the treatment of AA.

Conditions

Alopecia Areata

Study ID

NCT01802177

Start date

Feb, 2013

Status verified date

Jun, 2015

Primary completion date

Oct, 2015

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age > 18 years.
  • Subject has a patch of at least 12 cm2 on the scalp with no evidence of hair regrowth.
  • Subject is willing and capable of cooperating to the extent and degree required by the protocol.

Exclusion Criteria:

  • Patients who received treatment for alopecia areata within the past 4 weeks.
  • Patients with alopecia totalis or alopecia universalis.
  • Patients with known photosensitivity like having polymorphous light eruption, connective tissue diseases, porphyria or Xeroderma pigmentosum.
  • Pregnancy or breast-feeding.
  • History of previous skin cancer.
  • Patients that have participated in another investigational drug or device study within 30 days of enrollment.

Study Design

Enrollment

18 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: UVB excimer light

Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.

no intervention: No treatment (covered)

Interventions

UVB excimer light

Primary outcome measure

  • Change in the percentage of hair regrowth for each half. We will consider the treamtment successful if there was ≥50% hair regrowth from baseline. [ Time Frame: at 6, 12, and 16 weeks from baseline ]

Central Contacts and Locations

Central contacts

Harvey Lui, MD, FRCPC

16048754111harvey.lui@ubc.ca

Locations

The Skin Care Center, Vancouver General Hospital

Recruiting

Vancouver, British Columbia, Canada, V5Z 4E8

Contacts

Harvey Lui, MD FRCPC

16048754111harvey.lui@ubc.ca

Principal Investigator:

Harvey Lui, MD FRCPC

More Information

Sponsor

University of British Columbia

Last update posted

Jul 2, 2015

Last verified

Jun, 2015

Keywords

  • Alopecia areata
  • Excimer
  • UVB

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2015-07-02.